[go: up one dir, main page]

DE1695380B2 - 3 hydrazinopyridazindenvates and processes for their preparation - Google Patents

3 hydrazinopyridazindenvates and processes for their preparation

Info

Publication number
DE1695380B2
DE1695380B2 DE19681695380 DE1695380A DE1695380B2 DE 1695380 B2 DE1695380 B2 DE 1695380B2 DE 19681695380 DE19681695380 DE 19681695380 DE 1695380 A DE1695380 A DE 1695380A DE 1695380 B2 DE1695380 B2 DE 1695380B2
Authority
DE
Germany
Prior art keywords
hydrazino
morpholinopyridazine
hydrazinopyridazindenvates
processes
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19681695380
Other languages
German (de)
Other versions
DE1695380A1 (en
DE1695380C3 (en
Inventor
Elvio Albate Como Bellasio
Giulio Mailand Maffii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruppo Lepetit SpA
Original Assignee
Gruppo Lepetit SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruppo Lepetit SpA filed Critical Gruppo Lepetit SpA
Publication of DE1695380A1 publication Critical patent/DE1695380A1/en
Publication of DE1695380B2 publication Critical patent/DE1695380B2/en
Application granted granted Critical
Publication of DE1695380C3 publication Critical patent/DE1695380C3/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

R""R ""

in der R' und R" niedere Hydroxyalkylgruppen bedeuten oder R' und R" zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen gegebenenfalls durch niedere Alkylgruppen substituierten Morpholino- oder 4-Methylpiperazinorest bilden, R'" eine niedere Alkylgruppe und R"" eine niedere Alkyl- oder die Carboxygruppe bedeutet. in which R 'and R "mean lower hydroxyalkyl groups or R' and R" together with the Nitrogen atom to which they are attached, one optionally substituted by lower alkyl groups Morpholino or 4-methylpiperazino form, R '"a lower alkyl group and R" " means a lower alkyl or the carboxy group.

2. 3-(2-Isopropyliden-hydrazino)-6-morpholino-pyridazin. 2. 3- (2-Isopropylidene-hydrazino) -6-morpholinopyridazine.

3. 3 - [2 - (1 - Methylpropyliden) - hydrazino]-6-morpholino-pyridaziu. 3. 3 - [2 - (1 - Methylpropylidene) - hydrazino] -6-morpholino-pyridaziu.

4. 3 -(2 - Isopropyliden - hydrazino) - 6 - (4- methylpiperazino)-pyridazin. 4. 3 - (2 - Isopropylidene - hydrazino) - 6 - (4 - methylpiperazino) pyridazine.

5. Verfahren zur Herstellung der Verbindungen nach Anspruch 1, dadurch gekennzeichnet, daß man in an sich bekannter Weise eine Verbindung der allgemeinen Formel5. Process for the preparation of the compounds according to claim 1, characterized in that a compound of the general formula is used in a manner known per se

R"R "

N-N-

NH-NH,NH-NH,

N = NN = N

3535

in der R' und R" vorstehende Bedeutung haben, mit mindestens der äquimolaren Menge einer Carbonylverbindung der allgemeinen Formelin which R 'and R "have the preceding meaning, with at least the equimolar amount of one Carbonyl compound of the general formula

O = CO = C

R""R ""

in der R'" und R"" vorstehende Bedeutung haben, in einem Lösungsmittel umsetzt.in which R '"and R" "have the preceding meaning, is reacted in a solvent.

4545

Die Erfindung betrifft 3-Hydrazinopyridazinderivate der allgemeinen FormelThe invention relates to 3-hydrazinopyridazine derivatives of the general formula

R' R'"R 'R' "

5555

NH-N=CNH-N = C

N = NN = N

R""R ""

in der R' und R" niedere Hydroxyalkylgruppen be- ho deuten oder R' und R" zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen gegebenenfalls durch niedere Alkylgruppen substituierten Morpholino- oder 4-Methylpiperazinorest bilden, R'" eine niedere Alkylgruppe und R"" eine niedere Alkyl- oder die Carboxygruppe bedeutet.in which R 'and R "contain lower hydroxyalkyl groups or R 'and R "together with the nitrogen atom to which they are attached represent an optional by lower alkyl groups substituted morpholino or 4-methylpiperazino radical, R '"a lower alkyl group and R "" denotes a lower alkyl or the carboxy group.

Die Verbindungen gemäß der Erfindung lassen sich in an sich bekannter Weise durch Umsetzung einer Verbindung der allgemeinen Formel R'The compounds according to the invention can be in a manner known per se by reacting a Compound of the general formula R '

NH —NH,NH --NH,

N = NN = N

in der R' und R" die vorstehende Bedeutung haben, mit mindestens der äquimolaren Menge einer Carbonylverbindung der allgemeinen Formelin which R 'and R "have the preceding meaning, with at least the equimolar amount of a carbonyl compound the general formula

R'"R '"

O = CO = C

R""R ""

in der R'" und R"" die vorstehende Bedeutung haben, in einem Lösungsmittel erhalten.in which R '"and R" "have the above meaning, obtained in a solvent.

Die Verbindungen der Erfindung besitzen starke blutdrucksenkende Wirkung.The compounds of the invention have potent antihypertensive effects.

Wenn man z. B. 3-(2-Isopropyliden-hydrazino)-6-morpholinopyridazin und 3-[2-(l-Methylpropy'nden)-hydrazino]-6-morpholino-pyridazin intravenös an Hunde verabreichte, die mit Chloralose und Urethan anästhesiert waren, beobachtete man eine deutliche Verringerung des Blutdrucks. Die erhaltenen Ergebnisse sind in der Tabelle 1 zusammengestellt. Die in den Tabellen angegebenen Verbindungs-Nummern entsprechen den Nummern der nachfolgenden Beispiele.If you z. B. 3- (2-Isopropylidene-hydrazino) -6-morpholinopyridazine and 3- [2- (l-Methylpropy'nden) hydrazino] -6-morpholinopyridazine When administered intravenously to dogs anesthetized with chloralose and urethane, a marked increase was observed Decrease in blood pressure. The results obtained are shown in Table 1. The connection numbers given in the tables correspond to the numbers in the following Examples.

Tabelle 1Table 1

Verb.Verb. Anzahl
der
Hundenumber
the
dogs Dosis,
mg/kg
i.V. Dose,
mg / kg
iV Anfangs-
blutdnick,
mm HgAt first-
blood thin,
mm Hg 11 22 55 180180 22 11 170170 11 0,50.5 174174 22 0,10.1 175175 22 11 55 199199 11 11 192192 33 0,10.1 168168 44th 22 1010 192192 22 11 175175 33 0,10.1 172172 66th 11 55 182182 33 11 181181 22 0,10.1 160160 hydralazin
(1-Hydrazino-
phthalazin)hydralazine
(1-hydrazino
phthalazine) 2
2
72
2
7th 1
0,5
0,11
0.5
0.1 153
177
159153
177
159

Verringerung desReducing the

Blutdrucks, mm HgBlood pressure, mm Hg

' -90 -75 -80 -40'-90 -75 -80 -40

-115-115

-105 -60-105 -60

-110 -75 -55-110 -75 -55

-102 -95 -40 -50 -48 32-102 -95 -40 -50 -48 32

Die angegebenen Daten stellen die Durchschnittswerte des systolischen und diastolischen Blutdrucks der in den Versuchen behandelten Tiere dar. Der Druck wurde mit Hilfe eines »Pressor-Transduktors«, worunter man ein Manometer zum Messen des Blutdrucks versteht, das direkt an die Arteric angeschlossen wird, gemessen.The data presented represent the mean values of systolic and diastolic blood pressure of the animals treated in the experiments. The pressure was measured with the aid of a "pressor transducer", by which one understands a manometer for measuring the blood pressure, which is connected directly to the arteric is being measured.

Weitere Versuche wurden an Ratten mit durch die Niere verursachtem überdruck durchgeführt. Der überdruck war nach dem von G r ο 11 m a η in Proc. Soc. Exptl. Biol. Med., 57, 102 (1944), beschrie-Further experiments were carried out on rats with overpressure caused by the kidney. Of the Overpressure was according to the G rο 11 m a η in Proc. Soc. Exptl. Biol. Med., 57, 102 (1944), described-

benen Verfahren hervorgerufen worden. Es wurden Tiere verwendet, die mindestens 30 Tage zuvor behandelt worden waren und einen arteriellen Blutdruck von nicht unter 160 mm Hg aufwiesen. Die Verbindungen wurden 5 Tage lang einmal täglich an Gruppen von 3 bis 4 Ratten in den folgenden Dosen oral verabreicht: 5, 1, 0,5, 0,25, 0,1 mg/kg. Ein bekanntes Blutdruck senkendes Mittel, nämlich Hydralazin (1-Hydrazinophthalazin), wurde unter den gleichen Bedingungen als Vergleichssubstanz verwendet. Die klein- ι ο sten Dosen, bei denen sich die Verbindungen noch als wirksam erwiesen, sind in Tabelle 2 zusammengestellt, zusammen mit der entsprechenden LD50 bei Mäusen. Die bei anästhesierten Hunden beobachtete wirksame Dosis ist ebenfalls angegeben. Zur Bestimmung der LD50 wurden die Medikamente intraperitoneal verabreicht. Tabelle 2The same procedure has been brought about. Animals were used which had been treated at least 30 days beforehand and which had an arterial blood pressure of not less than 160 mm Hg. The compounds were orally administered to groups of 3 to 4 rats once a day for 5 days in the following doses: 5, 1, 0.5, 0.25, 0.1 mg / kg. A known antihypertensive agent, namely hydralazine (1-hydrazinophthalazine), was used as a comparative substance under the same conditions. The smallest doses at which the compounds were still found to be effective are listed in Table 2, together with the corresponding LD 50 in mice. The effective dose observed in anesthetized dogs is also given. To determine the LD 50 , the drugs were administered intraperitoneally. Table 2

Verbindung des
Versuchs Nr.Connection of the
Trial no.

(mg/kg)(mg / kg)

100
80
120
116
150
105
101100
80
120
116
150
105
101

Wirksame
Dosis mg/kg,Effective
Dose mg / kg,

orai bei
Ratten mit
überdruckorai at
Rats with
overpressure

0,25
0,25
0,50
0,25
0.50
0,25
10.25
0.25
0.50
0.25
0.50
0.25
1

Wirksame Dosis mg/kg, i.v. bei
anästhesierten
HundenEffective dose mg / kg, iv at
anesthetized
Dogs

0,1
0,10.1
0.1

0,250.25

0.10.1

0.250.25

0,10.1

0,50.5

3535

Hydralazin
(1-Hydrazinophthalazin) Hydralazine
(1-hydrazinophthalazine)

Als kleinste noch wirksame Dosis wird diejenige Dosis angesehen, die den Blutdruck um mindestens 40 mm Hg senkt. Die Werte hängen von mehreren Bedingungen ab und sind öfter untereinander unterschiedlich auf Grund der unterschiedlichen Empfindlichkeit der Individuen der gleichen Tiergruppe gegenüber den Medikamenten. Jedoch die Methode der Bestimmung des Blutdrucks ist sehr genau, und die Fehlergrenze ist mit Sicherheit nicht größer als ± 5%.The smallest effective dose is considered to be that dose which increases the blood pressure by at least 40 mm Hg lowers. The values depend on several conditions and are often different from one another due to the different sensitivity of the individuals to the same group of animals the drugs. However the method of determining blood pressure is very accurate and that Error limit is definitely not greater than ± 5%.

Aus der Tabelle geht hervor, daß die Toxizität in allen Fällen praktisch gleich ist, daß die Verbindungen gemäß der Erfindung jedoch bei beiden Tierarten wesentlich stärker wirksam sind ils Hydralazin.The table shows that the toxicity in all cases is practically the same as that of the compounds According to the invention, however, hydralazine is much more effective in both animal species.

Die folgenden Beispiele dienen der weiteren Erläuterung der Erfindung.The following examples serve to further illustrate the invention.

Beispiel 1
3-(2-Isopropyliden-hydrazino)-example 1
3- (2-isopropylidene hydrazino) -

6-morpholino-pyridazin6-morpholinopyridazine

20 g 3-Hydrazino-6-morpholino-pyridazin werden in 450 ml Aceton gelöst. Die Lösung wird auf 70 bis 80 ml eingeengt und auf Eis gekühlt. Die ausgeschiedene feste Substanz wird abfiltriert und die Flüssigkeit auf 50 ml eingeengt. Nach einigem Stehen kann eine zweite Charge gewonnen werden. Die vereinigten Chargen werden in siedendem Äthanol gelöst und durch Kühlen auskristallisiert. Ausbeute 19,3 g (80%); F. = 187 bis 1900C.20 g of 3-hydrazino-6-morpholinopyridazine are dissolved in 450 ml of acetone. The solution is concentrated to 70 to 80 ml and cooled on ice. The precipitated solid substance is filtered off and the liquid is concentrated to 50 ml. After standing for a while, a second batch can be obtained. The combined batches are dissolved in boiling ethanol and crystallized out by cooling. Yield 19.3 g (80%); F. = 187 to 190 0 C.

Beispiel 2
3-[2-(l-Methylpropyliden)-hydrazino]-Example 2
3- [2- (l-methylpropylidene) hydrazino] -

6-morpholino-pyridazin6-morpholinopyridazine

3,9 g 3-Hydrazino-6-morpholino-pyridazin und 1,74 g Methy]äthy]keton werden in wasserfreiem Äthanol unter Rückfluß erhitzt, bis vollständige Lösung eingetreten ist Nach dem Stehen über Nacht wird das Lösungsmittel im Vakuum bei 400C abgedampft. Der Rückstand wird aus Isopropyläther umkristallisiert. Ausbeute 4,23 g (85%); F. = 125 bis 127°C.3.9 g of 3-hydrazino-6-morpholino-pyridazine and 1.74 g methyl] äthy] ketone are heated under reflux in anhydrous ethanol, occurred until complete dissolution After standing overnight the solvent in vacuo at 40 0 C evaporated. The residue is recrystallized from isopropyl ether. Yield 4.23 g (85%); M.p. = 125 to 127 ° C.

Beispiel 3Example 3

3-[2-(l-Carboxyäthyliden)-hydrazino]-3- [2- (l-carboxyethylidene) hydrazino] -

6-morpholino-pyridazin6-morpholinopyridazine

3,90 g 3-Hydrazino-6-morpholino-pyridazin werden zu einer wäßrigen Lösung von 1,68 g Natriumbicarbonat und 1,76 g Brenztraubensäure gegeben Das Gemisch wird gerührt, bis vollständige Lösung eingetreten ist. Die Lösung wird filtriert, dann werden 7,65 ml 10%iger Salzsäure zugegeben. Es bildet sich ein gelber Niederschlag, der abfiltriert, mit Eiswasser gewaschen und im Vakuum über P2O5 getrocknet wird. Ausbeute 4,40 g (83%); F. = 204 bis 208°C.3.90 g of 3-hydrazino-6-morpholinopyridazine are added to an aqueous solution of 1.68 g of sodium bicarbonate and 1.76 g of pyruvic acid. The mixture is stirred until complete dissolution has occurred. The solution is filtered, then 7.65 ml of 10% hydrochloric acid are added. A yellow precipitate forms, which is filtered off, washed with ice water and dried in vacuo over P 2 O 5. Yield 4.40 g (83%); F. = 204 to 208 ° C.

Beispiel 4Example 4

3-(2-Isopropyliden-hydrazino)-6-(4-methylpiperazino)-pyridazin
4,17 g 3-Hydrazino-6-(4-methylpiperazino)-pyridazin werden in 20 ml heißem Aceton gelöst. Nach dem Stehen wird der ausgefallene Feststoff gesammelt und aus Aceton umkristallisiert. Ausbeute 4,27 g (86%); F. = 158 bis 1610C.3- (2-Isopropylidene hydrazino) -6- (4-methylpiperazino) pyridazine
4.17 g of 3-hydrazino-6- (4-methylpiperazino) pyridazine are dissolved in 20 ml of hot acetone. After standing, the precipitated solid is collected and recrystallized from acetone. Yield 4.27 g (86%); F. = 158 to 161 0 C.

Beispiele 5. 6 und 7Examples 5, 6 and 7

Die folgenden Verbindungen wurden im wesentlichen nach den in den vorstehenden Beispielen beschriebenen Verfahren hergestellt:The following compounds were made essentially according to those described in the preceding examples Process made:

Beispiel
5example
5

R'R '

CH2 — CH2 — OH
H3CCH 2 - CH 2 - OH
H 3 C

CH-CH2 CH-CH 2

CH — CH2
H3C
CH2 — CH2 — OHCH - CH 2
H 3 C
CH 2 - CH 2 - OH

Verbindung R"Connection R "

CH, — CH2 — OHCH, - CH 2 - OH

CH, — CH, — OHCH, - CH, - OH

R"-R "- R""R "" CH3 CH 3 C2H5 C 2 H 5 CH3 CH 3 CH3 CH 3 CH3 CH 3 CH3 CH 3

F., CF., C

200—202
(Monohydrochlorid)200-202
(Monohydrochloride)

173—175173-175

196—199
(Monohydrochlorid)196-199
(Monohydrochloride)

Claims (1)

Patentansprüche:Patent claims: 1. 3-Hydrazinopyrida:inderivate der allgemeinen Formel1. 3-hydrazinopyrida: inderivate of the general formula V-NH-N=CV-NH-N = C / N/ N N = NN = N R'"R '"
DE19681695380 1967-01-25 1968-01-12 3-hydrazinopyridazine derivatives and processes for their preparation Expired DE1695380C3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB3804/67A GB1168334A (en) 1967-01-25 1967-01-25 New Pharmacologically Active Pyridazines

Publications (3)

Publication Number Publication Date
DE1695380A1 DE1695380A1 (en) 1972-08-10
DE1695380B2 true DE1695380B2 (en) 1973-11-08
DE1695380C3 DE1695380C3 (en) 1974-07-04

Family

ID=9765208

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19681695380 Expired DE1695380C3 (en) 1967-01-25 1968-01-12 3-hydrazinopyridazine derivatives and processes for their preparation

Country Status (15)

Country Link
AT (1) AT271491B (en)
BE (1) BE709868A (en)
BR (1) BR6896485D0 (en)
CH (1) CH471132A (en)
DE (1) DE1695380C3 (en)
DK (1) DK117301B (en)
ES (1) ES349741A1 (en)
FI (1) FI47663C (en)
FR (2) FR1568058A (en)
GB (1) GB1168334A (en)
IL (1) IL29248A (en)
NL (1) NL6800466A (en)
NO (1) NO120683B (en)
SE (1) SE337382B (en)
YU (1) YU32078B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1298210A (en) * 1968-12-30 1972-11-29 Sandoz Ltd Improvements in or relating to dihalo-pyridazine derivatives
IT1054107B (en) * 1970-12-15 1981-11-10 Isf Spa NEW 3, HYDRAZINOPYRIDAZINE 6, SUBSTITUTED FOR ANTI-HYPERTEN SIVA ACTIVITIES AND THEIR PREPARATION
ATE3294T1 (en) * 1978-10-02 1983-05-15 Gruppo Lepetit S.P.A. 6-AMINOSUBSTITUTED N-PYRROLYL-3-PYRIDAZINAMINES, THEIR PREPARATION AND PHARMACEUTICAL ANTIHYPERTENSIVE COMPOSITIONS CONTAINING THEM.

Also Published As

Publication number Publication date
FR1568058A (en) 1969-05-23
GB1168334A (en) 1969-10-22
AT271491B (en) 1969-06-10
ES349741A1 (en) 1969-04-01
BR6896485D0 (en) 1973-05-10
IL29248A (en) 1971-10-20
FI47663C (en) 1974-02-11
NL6800466A (en) 1968-07-26
YU32078B (en) 1974-04-30
FR7580M (en) 1970-01-05
DK117301B (en) 1970-04-13
DE1695380A1 (en) 1972-08-10
CH471132A (en) 1969-04-15
SE337382B (en) 1971-08-09
BE709868A (en) 1968-05-30
NO120683B (en) 1970-11-23
FI47663B (en) 1973-10-31
DE1695380C3 (en) 1974-07-04
YU18468A (en) 1973-10-31

Similar Documents

Publication Publication Date Title
DE2235544C3 (en) 33-Disubstituted 1-methyl-1,2,4triazole derivatives and process for their preparation
DE2228363A1 (en) 1,4-DIHYDROPYRIDINE, METHOD FOR MANUFACTURING AND USE AS A MEDICINAL PRODUCT
DE2452691A1 (en) 2,6-DISUBSTITUTED PHENYLAMINOGUANIDINE COMPOUNDS
DD207719A5 (en) PROCESS FOR THE PREPARATION OF 2-GUANIDINO-4-HETEROARYLTHIAZOLENE
DE1445186B2 (en) 3,3'-di-2-imidazolin-2-yl-carbanilide
DE3326148C2 (en)
DE2921660A1 (en) 5-NITROIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND ANTIPROTOZONE AGENTS CONTAINING THESE COMPOUNDS
DE1695380C3 (en) 3-hydrazinopyridazine derivatives and processes for their preparation
DE1545772B1 (en) 7- (3'-picolylamino-alkyl) -theophyllins and their nicotinic acid salts
DE1965711C3 (en) l ^ -Dihydro-133-triazine derivatives, processes for their preparation and medicaments containing them
DE2221758A1 (en) Yohimbine derivatives, process for their preparation and their use
DE2923817C2 (en) (3-Alkylamino-2-hydroxyproposy) -furan-2-carboxylic acid anilides and their physiologically acceptable acid addition salts and processes for their preparation, as well as pharmaceuticals containing these compounds
DE3438244C2 (en)
DE2536170C3 (en) Flavone derivatives, processes for their preparation and pharmaceuticals containing these compounds
DE2819896A1 (en) CHROME DERIVATIVES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THE SAME
DE1925351A1 (en) Isopropylnorbornanamine
DE2526092A1 (en) N-2'-carboxyphenyl-anthranilic acid derivs. - which improve liver function, increase immunity to viral and bacterial infection and are used in auto-immune illness cancer and asthma
DE1795381C3 (en) Styrylthiazolium salts
DE1795384C3 (en) 1 H-2,3-Benzoxazines, processes for their production and pharmaceuticals
DE2310827C3 (en) Phenylalanine derivatives heterocyclically substituted in the phenyl nucleus
DE2725245A1 (en) METHYLAMINE DERIVATIVES, THE PROCESS FOR THEIR PRODUCTION AND THE PHARMACEUTICAL OR VETERINARY MEDICAL COMPOSITIONS THEREOF
EP0185988B1 (en) 10,11-Dihydro-5H-dibenzo[a,d]cycloheptadiene derivatives, their preparation and use
DE3116250A1 (en) "NONAPRENYLAMINE DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THEM"
DE2250856C3 (en) N high 1 -p-Chlorophenyl-N high 5- (1-alkyl-2-pyrrolidinylmethyl) biguanide
DE1695580C (en) Quaternary compounds of benzil acid beta piperidino ethyl ester and a process for their preparation

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
E77 Valid patent as to the heymanns-index 1977